4-(6-Phenylpyrazolo[1,5-a]pyrimidin-5-yl)benzaldehyde → HCID 178420107, 화합물
반응식
[C:1]1([C:7]2[C:8]([C:16]3[CH:23]=[CH:22][C:19]([CH:20]=O)=[CH:18][CH:17]=3)=[N:9][C:10]3[N:11]([N:13]=[CH:14][CH:15]=3)[CH:12]=2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.Cl.[NH:25]1[CH2:30][CH2:29][CH:28]([C:31]2[NH:39][C:34]3=[N:35][CH:36]=[CH:37][CH:38]=[C:33]3[N:32]=2)[CH2:27][CH2:26]1>CN(C=O)C>[C:1]1([C:7]2[C:8]([C:16]3[CH:23]=[CH:22][C:19]([CH2:20][N:25]4[CH2:26][CH2:27][CH:28]([C:31]5[NH:39][C:34]6=[N:35][CH:36]=[CH:37][CH:38]=[C:33]6[N:32]=5)[CH2:29][CH2:30]4)=[CH:18][CH:17]=3)=[N:9][C:10]3[N:11]([N:13]=[CH:14][CH:15]=3)[CH:12]=2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1참가 물질
4
실험 절차
251.4 mg (0.84 mmol) 4-(6-phenylpyrazolo[1,5-a]pyrimidin-5-yl)benzaldehyde, a suspension in 10 mL DMF and 238 mg (1 mmol) 2-piperidine-4-yl-3H-imidazo[4,5-b]pyridine hydrochloride salt were stirred and treated as described in example 15.0. After stirring overnight at room temperature, the reaction mixture was worked up as described in example 15. After purification 90 mg of the desired product were obtained.